FDA says Geodon journal ad omits risk info

Share this article:
The FDA says a professional journal ad for Pfizer's antipsychotic medication Geodon (ziprasidone mesylate) for injection omits important risk info and contains unsubstantiated superiority claims. It wants the company to submit a list of all materials to be pulled along with a plan for discontinuing its use, and Pfizer has agreed.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.